Table of Contents Table of Contents
Previous Page  103 / 812 Next Page
Information
Show Menu
Previous Page 103 / 812 Next Page
Page Background

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S72–S115

S99

The study group included 156 patients with schizophrenia receiv-

ing long-term antipsychotic treatment. Patients were divided into

two groups: 63 patients with TD and 93 patients without it. Glu-

tamate was determined in serum by spectrophotometric method.

Determination of allelic variants of gene SLC1A2 (rs4354668) and

GRIN2A (rs2650427, rs1969060) was performed by polymerase

chain reaction in real-time.

We found a significant (

P

< 0.05) increase of the concentration

of glutamate in patients with TD. Significant (

P

< 0.05) reduction

in frequency of genotype GG of GRIN2A (rs1969060) and TT of

SLC1A2 (rs4354668) were found in patients with TD in compari-

son to group without TD. In the study of glutamate concentration

depending on the genotype GRIN2A (rs1969060) and genotype

SLC1A2 (rs4354668) we observed a statistically significant change:

elevated levels of glutamic acid identified with the heterozygous

genotype in patients.

It is possible to suggest that reduction in frequency of these

genotypes increases the risk of movement disorders due to the

protective effect of these genotypes.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.069

FC66

Cognitive function in female patients

with schizophrenia and metabolic

syndrome

A.C. Botis

1 ,

, I. Miclutia

1

, N. Vlasin

2

1

University of Medicine and Pharmacy Cluj-Napoca, Psychiatry and

pediatric psychiatry, Cluj-Napoca, Romania

2

Emergency County Hospital Cluj-Napoca, Psychiatry, Cluj-Napoca,

Romania

Corresponding author.

Introduction

The metabolic syndrome (MetS) and cognitive

impairments, both related with poor outcomes in schizophrenia,

are common in patients with this disorder. MetS has been associ-

ated with cognitive impairments in schizophrenia, but there is no

general consensus regarding the description of various domains of

neurocognition in patients with schizophrenia related to MetS.

Objectives

The goal of this study was to assess cognitive func-

tions in female patients with schizophrenia complicated by

metabolic syndrome compared to those with schizophrenia with-

out metabolic syndrome.

Methods

Fifty-four female patients diagnosed with schizophre-

nia were divided into two groups: MetS group (MetS+) and

non-MetS group (MetS

). Cognitive functioning were investigated

using the Brief Assessment of Cognition in Schizophrenia (BACS).

Results

Twenty-seven (52%) patients with schizophrenia met

criteria for the MetS diagnosis. Mean age of patients was 40.80.

Patients from MetS+ group performed significantly worse on

verbal memory (

P

= 0.005), executive functions (

P

= 0.028) and

motor speed (

P

= 0.035) as compared to MetS

group. Patients

with schizophrenia who were hypertensive showed cognitive

impairments in 2 domains of cognition: attention and speed of

information processing (

P

= 0.004) and verbal fluency (

P

= 0.001).

Patients with hypertriglyceridemia performed significantly worse

on verbal memory (

P

= 0.005). Motor speed was associated with

waist circumference (

P

= 0.02).

Conclusions

At a mean age of 40 years old, female patients with

schizophrenia and metabolic syndrome show difficulties in more

domains of cognitive function compared to female patients with

schizophrenia without metabolic syndrome. Our findings suggest a

link between cognition and metabolic syndrome in female patients

with schizophrenia.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.070

FC67

Comparing cognitive functions in

medication adherent and

non-adherent patients with

schizophrenia

A. El-Missiry

Ain Shams University, Neurology & Psychiatry, Cairo, Egypt

Background

Medication non-adherence presents a considerable

problem in patients with schizophrenia. Cognitive and executive

functions can affect adherence. The association between medica-

tion non-adherence and cognitive impairment in schizophrenia is

under investigated with limited and conflicting research data.

Purpose of the study

To prospectively assess the rate of drug

adherence among a sample of patients with schizophrenia and to

compare the cognitive and executive functions between adherent

and non-adherent patients.

Subjects and methods

One hundred and nine patients with

schizophrenia diagnosed according to the DSM-IV classification

were initially assessed by the Wechsler Adult Intelligence Scale

(WAIS), Wechsler Memory Scale-Revised (WMS-R) and Wiscon-

sin Card Sorting Test (WCST) and six months later by the Brief

Adherence Rating Scale (BARS).

Results

Among the patients, 68.8% were non-adherent to their

antipsychotic medication. Adherent patients (31.2%) had signifi-

cantly higher mean scores for the total, verbal and performance

IQ. Moreover, they had significantly higher mean scores in most

of WMS subtests (orientation, information, verbal paired associ-

ation, digit span, visual memory span), and higher mean scores

for; total correct, conceptual level response, percentage and cat-

egories completed on the WSCT subscales (

P

< 0.0001). Whereas

the non-adherent group had higher mean scores in; trials admin-

istered, total errors, perseverative responses, and perseverative

errors (

P

< 0.0001). In a step regression analysis, digit span, concep-

tualization, total and percentage of errors were putative predictors

of non-adherence to antipsychotic medications.

Conclusion

Cognitive deficits, especially verbal memory and

executive functions were the strongest patients’ related factors

associated with non-adherence to medication. Psychiatrists should

consider possible cognitive factors influencing adherence to enable

offering proper interventions.

Disclosure of interest

The author has not supplied his declaration

of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.071

FC68

Peripheral sub-inflammation is

associated with antidepressant

consumption in schizophrenia.

Results from the multi-center

FACE-SZ dataset

G. Fond

1 ,

, O. Godin

1

, P.M. Llorca

2

, M. Leboyer

1

1

Schizophrenia Expert Center Fondation Fondamental, Créteil, France

2

Schizophrenia Expert Center Fondation Fondamental,

Clermont-Ferrand, France

Corresponding author.

Objectives

The relation between C-reactive protein (CRP),

depression and antidepressant consumption has been well

explored in major depressive disorders but not in schizophrenia,

which has a high rate of depression comorbidity. The objectives of

this study were:

– to determine the prevalence of abnormal CRP levels, depression

and antidepressant consumption in a multi-center community-

dwelling sample of subjects with schizophrenia;

– to determine the association between abnormal CRP levels,

depression and antidepressant consumption in schizophrenia.